To reduce the burden of PrCA among all men, there has been fervent controversy about the routine use of the prostate specific antigen (PSA) screening as a prevention measure (Carlsson et al., 2012; Catalona, 2012). The gene discussed is KLK3; the disease is pure red-cell aplasia.